Equities research analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a report released on Saturday. The firm set a "sell" rating on the stock.
InspireMD Stock Up 0.8 %
Shares of NYSE:NSPR traded up $0.02 during midday trading on Friday, hitting $2.57. The stock had a trading volume of 327 shares, compared to its average volume of 52,851. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.80. The business's 50-day simple moving average is $2.82 and its 200-day simple moving average is $2.74. The company has a market cap of $78.73 million, a P/E ratio of -3.43 and a beta of 0.74.
Institutional Trading of InspireMD
Large investors have recently made changes to their positions in the company. Parkman Healthcare Partners LLC raised its stake in InspireMD by 721.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock worth $2,248,000 after buying an additional 750,635 shares during the last quarter. Affiance Financial LLC lifted its holdings in InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock worth $497,000 after acquiring an additional 5,376 shares during the period. Essex Investment Management Co. LLC purchased a new stake in InspireMD in the fourth quarter worth $191,000. Northern Trust Corp increased its position in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after buying an additional 24,452 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after purchasing an additional 18,233 shares in the last quarter. Institutional investors and hedge funds own 44.78% of the company's stock.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Further Reading
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
